Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0N9WA)

Drug Name
Calcitonin Human Drug Info
Indication
Disease Entry ICD 11 Status REF
Paget's disease FB85 Approved [1]
Pain MG30-MG3Z Phase 3 [2]
Postmenopausal osteoporosis FB83.11 Phase 3 [2]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
45055432
ChEBI ID
CHEMBL135973
TTD Drug ID
DM0N9WA

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcitonin receptor (CALCR) TTLWS2O CALCR_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Calcitonin receptor (CALCR) DTT CALCR 5.326 4.489 4.213 5.07
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Paget's disease
ICD Disease Classification FB85
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcitonin receptor (CALCR) DTT CALCR 7.52E-03 0.17 2.26
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27(8):1821-9.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.